By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TG Therapeutics, Inc. 

787 Seventh Avenue
48th Floor
New York  New York  10019  U.S.A.
Phone: 212-554-4484 Fax: 212-554-4531


SEARCH JOBS


Industry
Pharmaceutical






Company News
TG Therapeutics (TGTX) Recaps Positive Data From The Phase III GENUINE Trial And Data From The Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 14th International Conference On Malignant Lymphoma 6/16/2017 9:02:05 AM
TG Therapeutics (TGTX) Announces Follow-Up Data For Combination Of TGR-1202 (Umbralisib) Plus Ibrutinib In Patients With Relapsed Or Refractory CLL And MCL At The 14th International Conference On Malignant Lymphoma 6/14/2017 12:17:09 PM
TG Therapeutics (TGTX) Announces Follow-Up Data From The Chemo-Free Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 53rd Annual Meeting Of The ASCO 6/5/2017 11:53:40 AM
TG Therapeutics (TGTX) Announces Successful Outcome From Pre-Planned Interim Analysis By Independent DSMB In The UNITY-CLL Phase III Trial 5/23/2017 11:15:20 AM
TG Therapeutics (TGTX) Recaps Clinical Data Presentations At The Upcoming 53rd Annual Meeting Of The ASCO 5/18/2017 12:29:19 PM
TG Therapeutics (TGTX): Significant Near-Term Catalysts For 2017 5/16/2017 6:07:37 AM
TG Therapeutics (TGTX) Provides Business Update And Reports First Quarter 2017 Financial Results 5/5/2017 10:54:22 AM
TG Therapeutics (TGTX) Announces Preliminary Results From Ongoing Phase II Study Of TG-1101 (Ublituximab) In Patients With Multiple Sclerosis At The American Academy of Neurology 4/28/2017 8:24:46 AM
TG Therapeutics (TGTX) Rockets After Leukemia Drug Clears Hurdle in Late-Stage Study 3/6/2017 7:22:16 AM
TG Therapeutics, Inc. (MHA) Stock Plunges as Company Modifies Phase III Cancer Trial Protocols 10/14/2016 6:38:28 AM
12345678910...
//-->